Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + Bevacizumab + TACE vs TACE alone in Hepatocellular Carcinoma
NCT04712643Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Mar 2021
- Primary completion
- Feb 2029
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of atezolizumab, bevacizumab in hepatocellular carcinoma (HCC), sponsored by Roche. Started Mar 2021; status: active, not recruiting.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04712643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04712643.